Clinical Trial Network for Pivotal FDA Study Complete
Filed with ASX · · 5 pages · English
Summary by 6ix AI
BlinkLab Limited has announced the completion of its clinical trial network for a pivotal FDA study, with the University of Arkansas joining as the tenth clinical site. Participant recruitment for the study is expected to commence soon, following the onboarding of leading clinical sites across the U.S.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Blinklab
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- High-Profile Journal Publication Validates BB1 Technology
- Appointment of Managing Director and Board Changes
- Pilot Study Confirms High Diagnostic Accuracy & Readiness
Later from Blinklab
- Trading Halt
- Morocco's Nationwide Government-Funded Autism Screening
- Validation Program Commences-FDA 510(k) - First Participant
- BlinkLab Launches Pivotal US FDA Trial for AI Smartphone Autism Diagnostic
- BlinkLab Secures A$17.5M to Launch Autism Diagnostic Aid
Follow Blinklab into a list and get an email when it puts out news.
Follow Blinklab